Imunon Inc
IMNN
查看详细走势图
3.270USD
+0.170+5.48%
收盘 02/06, 16:00（美东）报价延迟15分钟
10.89M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+5.48%
5天
-1.51%
1月
-16.58%
6月
-52.95%
今年开始到现在
-14.17%
1年
-72.08%
查看详细走势图
TradingKey Imunon Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Imunon Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名116/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价60.90。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Imunon Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Imunon Inc亮点
亮点风险
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
估值低估
公司最新PE估值-0.42，处于3年历史低位
机构减仓
最新机构持股162.10K股，环比减少44.83%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值37.05K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.97
分析师目标
根据
4
位分析师
买入
评级
63.902
目标均价
+1948.15%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Imunon Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Imunon Inc简介
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
公司代码IMNN
公司Imunon Inc
CEOLindborg (Stacy R)
网址https://imunon.com/
相关品种
